CLINICAL TRIALS PROFILE FOR MIRVASO
✉ Email this page to a colleague
All Clinical Trials for Mirvaso
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02249065 ↗ | Mirvaso in Use Study | Completed | Galderma Laboratories, L.P. | Phase 4 | 2014-09-01 | This study is designed to: 1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel 2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment 3. gain a better understanding of the real-world use of Mirvaso® on the pattern and management of facial erythema of rosacea. |
| NCT02289352 ↗ | Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea | Completed | Watson Laboratories, Inc. | Phase 3 | 2014-07-01 | A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients with Moderate to Severe Facial Erythema Associated with Rosacea |
| NCT02289352 ↗ | Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea | Completed | Actavis Inc. | Phase 3 | 2014-07-01 | A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients with Moderate to Severe Facial Erythema Associated with Rosacea |
| NCT02568111 ↗ | Brimonidine Tartrate for the Treatment of Injection Related Erythema | Withdrawn | Biogen | Phase 4 | 2016-02-01 | The primary objective of this study is to evaluate the Injection Related Erythema (IRE) mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel (placebo). The secondary study objectives are to evaluate the IRE mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel on a more stringent definition scale, in accordance with the primary endpoint of the original brimonidine pivotal trials and participants' satisfaction with the overall appearance of their skin. |
| NCT02616250 ↗ | MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. | Completed | Galderma | Phase 4 | 2015-12-01 | The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea. |
| NCT02616250 ↗ | MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. | Completed | Galderma R&D | Phase 4 | 2015-12-01 | The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea. |
| NCT02659670 ↗ | Internet Surveys and Their Impact on Adherence for Rosacea | Completed | Wake Forest University Health Sciences | Phase 4 | 2016-05-05 | An investigator-blinded, prospective, 6 month study of subjects with persistent erythema associated with active rosacea will be conducted in 20 subjects aged 18 years and older. All subjects will receive standard-of-care brimonidine topical gel, 0.33% with instructions to apply it once daily per package insert. Adherence will be assessed using weekly internet surveys to document how often the medication is being used, as well as reminders about rosacea triggers and general use of brimonidine. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Mirvaso
Condition Name
Clinical Trial Locations for Mirvaso
Trials by Country
Clinical Trial Progress for Mirvaso
Clinical Trial Phase
Clinical Trial Sponsors for Mirvaso
Sponsor Name
